Target intelligence / Profile preview

Bet v 1

Target
Bet v 1
Molecular classification
Pathogenesis-related class PR-10 protein, Allergen
01

Overview

Bet v 1 is the major allergen from birch (Betula verrucosa) pollen and serves as the prototype for the pathogenesis-related class 10 (PR-10) protein family. It is a small, cytosolic protein with a molecular weight of approximately 17–17.5 kDa. Bet v 1 adopts a characteristic fold consisting of a curved seven-stranded antiparallel β-sheet, two short α-helices, and an extended C-terminal helix that together create an enlarged inner cavity typical for PR-10 proteins. The large hydrophobic cavity functions as a ligand-binding site for various small molecules such as lipids, hormones, flavonoids, and siderophores. Multiple isoforms exist with minor sequence variations but significant differences in IgE-binding capacity. It is believed to play roles in plant defense mechanisms against pathogens or stress conditions. In its apo-form (unbound by iron), Bet v 1 can prime T cells toward Th2 responses, while holo-form (iron-bound) may suppress immune activation via induction of apoptosis in immune cells. Binding ligands stabilizes the conformation of Bet v 1.

Other names
Bet v 1.0101Bet v 1.0201Bet v 1.0102PR-10 protein
02

Mechanism of action

N/A

03

Biological functions

Plant defenseLigand bindingStorageImmune response modulation
04

Disease associations

AllergyBirch pollen allergy
05

Safety considerations

AllergenicityCross-reactivity with other tree pollens (alder, hazel)
06

Biomarkers

IgE reactivity to Bet v 1

Beyond the preview

Go deeper on Bet v 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bet v 1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call